Lu-177-PSMA-617 radioligand therapy in mCRPC: ready for phase III trial?

Rahbar Kambiz; Ahmadzadehfar Hojjat; Boegemann Martin

首页> 外文期刊>European Journal of Nuclear Medicine and Molecular Imaging >Lu-177-PSMA-617 radioligand therapy in mCRPC: ready for phase III trial?

【24h】

Lu-177-PSMA-617 radioligand therapy in mCRPC: ready for phase III trial?

机译：Lu-177-PSMA-617在MCRPC中的放射性配体疗法：准备好阶段III试验？

获取原文

获取原文并翻译 | 示例

掌桥外文数据库（机构版） >>

开具论文收录证明 >>

页面导航

著录项
相似文献
相关主题

著录项

来源
《European Journal of Nuclear Medicine and Molecular Imaging》 |2018年第3期|共2页
作者
Rahbar Kambiz; Ahmadzadehfar Hojjat; Boegemann Martin;
展开▼
作者单位

Univ Hosp Muenster Dept Nucl Med D-48149 Munster Germany;

Univ Hosp Bonn Dept Nucl Med Bonn Germany;

Univ Hosp Muenster Dept Urol Munster Germany;

展开▼
收录信息
原文格式 PDF
正文语种 eng
中图分类放射医学;
关键词
入库时间 2022-08-20 02:47:00

相似文献

外文文献
中文文献
专利

1. Lu-177-PSMA-617 radioligand therapy in mCRPC: ready for phase III trial? [J] . Rahbar Kambiz, Ahmadzadehfar Hojjat, Boegemann Martin European Journal of Nuclear Medicine and Molecular Imaging . 2018,第3期

机译：Lu-177-PSMA-617在MCRPC中的放射性配体疗法：准备好阶段III试验？
2. Lu-177-PSMA-617 radioligand therapy of mCRPC: evaluation criteria of response [J] . Rahbar Kambiz, Boegemann Martin, Ahmadzadehfar Hojjat European Journal of Nuclear Medicine and Molecular Imaging . 2017,第1期

机译：Lu-177-PSMA-617 MCRPC的放射性配体疗法：评估标准的反应
3. Autologous dendritic cell immunotherapy (DCVAC/PCa) added to docetaxel chemotherapy in a Phase III trial (viable) in men with advanced (mCRPC) prostate cancer [J] . Tomasz M Beer, Nicholas Vogelzang, Ji?ina Bart?ňková, Journal for ImmunoTherapy of Cancer . 2015,第S2期

机译：在晚期（mCRPC）男性男性患者的III期临床试验（可行）中，自体树突状细胞免疫疗法（DCVAC / PCa）加入多西他赛化疗中
4. Molecular Therapies in Hepatocellular Carcinoma beyond Sorafenib: Lessons from Failed Phase III Trials and Novel Targets [C] . Lipika Goyal, Andrew X. Zhu Gastrointestinal Cancers Symposium . 2014

机译：Sorafenib之外的肝细胞癌中的分子疗法：III期试验失败的课程和新型靶标
5. Examination of novel statistical designs for phase II and phase III clinical trials. [D] . Ayanlowo, Ayanbola Olajumoke. 2007

机译：检验II期和III期临床试验的新颖统计设计。
6. Autologous dendritic cell immunotherapy (DCVAC/PCa) added to docetaxel chemotherapy in a Phase III trial (viable) in men with advanced (mCRPC) prostate cancer [O] . Tomasz M Beer, Nicholas Vogelzang, Jiřina Bartůňková, 2015

机译：在晚期（mCRPC）男性患者的III期临床试验（可行）中自体树突状细胞免疫疗法（DCVAC / PCa）加入多西他赛化疗中
7. Autologous dendritic cell immunotherapy (DCVAC/PCa) added to docetaxel chemotherapy in a Phase III trial (viable) in men with advanced (mCRPC) prostate cancer [O] . 2015

机译：一项针对晚期前列腺癌（mCRPC）的男性患者的三期试验（可行）中，自体树突状细胞免疫疗法（DCVAC / PCa）加入多西他赛化疗中

Lu-177-PSMA-617 radioligand therapy in mCRPC: ready for phase III trial?

著录项

相似文献

相关主题

期刊订阅